Abstract:Sorting nexin-1 (SNX1) is an important functional protein in cell endocytosis, efflux, protein sorting, cell signal transduction, etc; however, the expression, the role and clinical relevance of SNX1 have not been investigated in gastric cancer (GC). In this study, we first performed a bioinformatics investigation using the data obtained from The Cancer Genome Atlas (TCGA) database. The result showed that SNX1 mRNA levels were significantly lower in GC tissues than in paracancerous tissues. In a study of 150 cases of GC, including 60 cases with paired paracancerous and cancer tissues and 90 cases with detailed follow-up information, SNX1 expression was analyzed by immunohistochemistry. Our study on paired paracancerous and cancer tissues showed that SNX1 protein expression remarkably decreased in GC tissues (50/60, 83.33%). A study on 90 patients with detailed follow-up information showed that tumors with higher SNX1 protein level were correlated with better clinicopathologic stages (p = 0.0285), nodal status (p = 0.0286), smaller tumor sizes (p = 0.0294) and a better survival rate in patients with GC (p = 0.0245). Univariate analysis of the 90 patients with GC showed that low-level SNX1 was significantly correlated with decreased overall survival of GC patients (p = 0.008), and associated with a relatively higher cumulative hazard of death. Exogenous expression of SNX1 inhibited the growth, migration, invasion and promoted the apoptosis and enhanced the sensitivity of GC cells to the chemotherapeutic drug 5-Fluorouracil (5-Fu) in vitro, while knockdown of SNX1 by short hairpin RNA (shRNA) significantly promoted the growth, migration, invasion and reduced the apoptosis and the sensitivity of GC cells to 5-Fu. SNX1 also showed to influence the levels of epithelial-mesenchymal transition markers including Vimentin, Snail, and E-cadherin in GC cells in vitro. Taken together, we propose here that SNX1 serves as a tumor suppressor and prognostic marker that reduces tumor cell malignancy for GC.

Sorting Nexins: A Novel Promising Therapy Target For Cancerous/Neoplastic Diseases

Sorting Nexins Family and Endosomal Sorting Network

The Research Status of the Sorting Nexins Family

Sorting Out Sorting Nexins Functions in the Nervous System in Health and Disease

Endosomal localization and function of sorting nexin 1

Sorting nexin-1 mediates tubular endosome-to-TGN transport through coincidence sensing of high- curvature membranes and 3-phosphoinositides

Identification of a family of sorting nexin molecules and characterization of their association with receptors

Canonical and Non-Canonical Roles of SNX1 and SNX2 in Endosomal Membrane Dynamics

Evidence for a Role of SNX16 in Regulating Traffic Between the Early and Later Endosomal Compartments

A role for sorting nexin 2 in epidermal growth factor receptor down-regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein trafficking

Sorting Nexin 10 Acts As a Tumor Suppressor in Tumorigenesis and Progression of Colorectal Cancer Through Regulating Chaperone Mediated Autophagy Degradation of P21cip1/waf1.

Sorting Nexins in Protein Homeostasis

Sorting Nexin 5 Controls Head and Neck Squamous Cell Carcinoma Progression by Modulating FBW7

SNX9 promotes metastasis by enhancing cancer cell invasion via differential regulation of RhoGTPases

Deficiency of Sorting Nexin 27 (snx27) Leads to Growth Retardation and Elevated Levels of N-Methyl-D-Aspartate Receptor 2c (Nr2c)

Inhibiting SNX10 induces autophagy to suppress invasion and EMT and inhibits the PI3K/AKT pathway in cervical cancer

Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting

SNX3 Regulates Endosomal Function Through Its PX-domain-mediated Interaction with PtdIns(3)P

SNX10 (sorting Nexin 10) Inhibits Colorectal Cancer Initiation and Progression by Controlling Autophagic Degradation of SRC.

Sorting Nexin-1 is a Candidate Tumor Suppressor and Potential Prognostic Marker in Gastric Cancer

SNX16 is required for hepatocellular carcinoma survival via modulating the EGFR-AKT signaling pathway